RJA
BMY icon

Raymond James & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Raymond James & Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,500
Closed -$609K – 4003
2024
Q2 		$609K Buy
+14,500
New +$649K ﹤0.01% 2942
2019
Q1 		– Sell
-20,000
Closed -$59K – 3625
2018
Q4 		$59K Buy
+20,000
New +$1.07M ﹤0.01% 3369

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's BMY Position: Q3 2024 in Review

Raymond James & Associates increased its Bristol-Myers Squibb (BMY) stake by 0.9% in Q3 2024, buying an estimated $1.34M and bringing the position to 3,215,555 shares worth $166M. The position accounts for 0.1% of the portfolio, ranked #175.

Raymond James & Associates first reported a position in BMY in Q2 2013 and has held it in 46 quarters since. The position peaked at $275M in Q1 2022. 2,259 funds tracked by Wall St. Rank hold BMY as of Q3 2024.

  • Raymond James & Associates held 3,215,555 shares of Bristol-Myers Squibb worth $166M as of Q3 2024.
  • Raymond James & Associates bought 28,528 Bristol-Myers Squibb shares in Q3 2024, an estimated $1.34M.
  • Bristol-Myers Squibb made up 0.1% of Raymond James & Associates's portfolio in Q3 2024, its #175 holding.
  • Raymond James & Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Bristol-Myers Squibb position peaked at $275M in Q1 2022.
  • 2,259 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.